Literature DB >> 10343255

Esophagectomy with gastric reconstruction for achalasia.

M K Banbury1, T W Rice, J R Goldblum, S B Clark, M E Baker, J E Richter, L A Rybicki, E H Blackstone.   

Abstract

PURPOSE: Achalasia is a degenerative esophageal disorder that may result in esophageal failure necessitating resection for restoration of gastrointestinal function. This study evaluates a protocol of esophageal resection and gastric reconstruction for end-stage achalasia.
METHODS: Hospital records, radiographic studies, and resection specimens of patients undergoing esophagectomy and gastric reconstruction were reviewed. Patient outcome was defined by an evaluation of symptoms (early satiety, dysphagia, regurgitation, and reflux), dietary restrictions, and ability to maintain or gain weight. Preoperative, operative, and postoperative variables and pathologic features in the resection specimens were analyzed to determine predictors of outcome.
RESULTS: In a 10-year period, 32 patients underwent esophagectomy with gastric reconstruction for achalasia; 30 (94%) underwent elective surgery and 2 (6%), emergency surgery. No postoperative deaths occurred. Of 29 patients completing telephone interviews, 24 (83%) had no or mild dysphagia; 21 (72%), no or mild regurgitation; 20 (69%), no or mild reflux; and 19 (66%), no or mild early satiety. Twenty-four (83%) patients had no or minimal dietary restrictions; 26 (90%) had no or minimal social dietary restrictions. Postoperative weight was not different from preoperative weight. Of 30 patients, 26 (87%) felt better after esophagectomy and 25 (83%) would have the operation again. There were few predictors of outcome. Younger patients were more likely to have dysphagia ( P =.03).
CONCLUSIONS: Esophagectomy with gastric reconstruction relieves preoperative dysphasia and regurgitation in the majority of patients. Dietary function and weight maintenance are excellent, attesting to the durability of the procedure in patients with end-stage achalasia.

Entities:  

Mesh:

Year:  1999        PMID: 10343255     DOI: 10.1016/s0022-5223(99)70243-6

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Laparoscopic transhiatal esophagectomy for 'sigmoid' megaesophagus following failed cardiomyotomy: experience of 11 patients.

Authors:  Chinnusamy Palanivelu; Muthukumaran Rangarajan; Priyadarshan Anand Jategaonkar; Gobi Shanmugam Maheshkumaar; Natesan Vijay Anand
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

Review 2.  Management of idiopathic achalasia: short-term and long-term outcomes.

Authors:  B T Massey
Journal:  Curr Gastroenterol Rep       Date:  2000-06

3.  Esophagectomy for end-stage achalasia.

Authors:  Thomas J Watson
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

4.  Esophagectomy for End-Stage Achalasia.

Authors:  John Waters; Linda W Martin; Daniela Molena
Journal:  World J Surg       Date:  2022-04-03       Impact factor: 3.282

5.  Outcomes of esophagectomy for esophageal achalasia in the United States.

Authors:  Daniela Molena; Benedetto Mungo; Miloslawa Stem; Richard L Feinberg; Anne O Lidor
Journal:  J Gastrointest Surg       Date:  2013-08-21       Impact factor: 3.452

6.  Minimally invasive surgical treatment of sigmoidal esophagus in achalasia.

Authors:  Matthew J Schuchert; James D Luketich; Rodney J Landreneau; Arman Kilic; Yun Wang; Miguel Alvelo-Rivera; Neil A Christie; Sebastien Gilbert; Arjun Pennathur
Journal:  J Gastrointest Surg       Date:  2009-03-27       Impact factor: 3.452

Review 7.  Esophagectomy for End-Stage Achalasia: Systematic Review and Meta-analysis.

Authors:  Alberto Aiolfi; Emanuele Asti; Gianluca Bonitta; Luigi Bonavina
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

8.  Thoracoscopic oesophagectomy for end-stage achalasia.

Authors:  Vaibhav Kumar Varshney; Subhash Chandra Soni; Manju Kumari; Pawan Kumar Garg; Ashok Puranik
Journal:  J Minim Access Surg       Date:  2018 Jul-Sep       Impact factor: 1.407

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.